Literature DB >> 21849124

[HIF-1α siRNA reduces retinal neovascularization in a mouse model of retinopathy of prematurity].

Hui-Zhuo Xu1, Shuang-Zhen Liu, Si-Qi Xiong, Xiao-Bo Xia.   

Abstract

OBJECTIVE: To study the inhibition effect of HIF-1α specific siRNA expression vector pSUPERH1-siHIF-1α on retinal neovascularization in a mouse model of retinopathy of prematurity (ROP).
METHODS: The mouse model of ROP was prepared by the method Smith described. Forty-eight ROP mice were randomly divided into two groups: an experimental group that was intravitreously injected with pSUPERH1-siHIF-1α and a control group that was injected with pSUPER retro vector. The levels of HIF-1α and vascular endothelia growth factor (VEGF) in the retina were examined by Western blot. The retinal neovascularization was evaluated by angiography using FITC Dextran and quantitated histologically.
RESULTS: The levels of HIF-1α and VEGF in the retina in the experimental group were reduced 90% and 65% respectively compared with those in the control group. Meanwhile, the number of retinal neovascular endothelial nucleus outbreaking the inner limit membrane in the experimental group was significantly reduced compared with that in the control group.
CONCLUSIONS: The development of retinal neovascularization of ROP can be markedly inhibited by RNA interference targeting HIF-1α.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21849124

Source DB:  PubMed          Journal:  Zhongguo Dang Dai Er Ke Za Zhi        ISSN: 1008-8830


  2 in total

1.  The siRNA-Mediated Down-Regulation of Vascular Endothelial Growth Factor Receptor1.

Authors:  Moslem Jafari Sani; Foad Yazdi; Masoomeh Masoomi Karimi; Javad Alizadeh; Majid Rahmati; Ali Zarei Mahmudabadi
Journal:  Iran Red Crescent Med J       Date:  2016-02-02       Impact factor: 0.611

2.  Identified a disintegrin and metalloproteinase with thrombospondin motifs 6 serve as a novel gastric cancer prognostic biomarker by bioinformatics analysis.

Authors:  Ya-Zhen Zhu; Yi Liu; Xi-Wen Liao; Shan-Shan Luo
Journal:  Biosci Rep       Date:  2021-04-30       Impact factor: 3.840

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.